Topics A-Z:

›› Topics A-Z

Search the site:

›› Advanced search

Home › Topics › Infectious Diseases › Infections A-Z › Acinetobacter species › Surveillance ›Voluntary surveillance data 2003 - 2007 › Antibiotic susceptibility data

Printer friendly page (opens in new window)

Antibiotic susceptibility data

Tables 3 and 4 present antibiotic susceptibility data for A. calcoaceticus/baumannii and A. lwoffii, respectively.

Table 3 Antibiotic susceptibility data for reports of A. calcoaceticus/baumannii bacteraemia, England, Wales, and Northern Ireland: 2003 to 2007*

*A. calcoaceticus/baumannii*	2003	2004	2005	2006	2007
Total reports:	359	374	400	413	399
Gentamicin	% Non-susceptible Reports with susceptiblility data	22% 237	26% 285	23% 276	26% 313	21% 331
Amikacin	% Non-susceptible Reports with susceptiblility data	11% 85	16% 91	21% 115	26% 187	22% 199
Tobramycin	% Non-susceptible Reports with susceptiblility data	12% 51	14% 50	23% 71	25% 93	32% 114
Ciprofloxacin	% Non-susceptible Reports with susceptiblility data	30% 231	36% 266	30% 269	36% 319	30% 326
Imipenem	% Non-susceptible Reports with susceptiblility data	7% 82	5% 73	9% 94	21% 126	24% 173
Meropenem	% Non-susceptible Reports with susceptiblility data	3% 95	13% 128	20% 126	35% 175	22% 175
Cefotaxime	% Non-susceptible Reports with susceptiblility data	80% 121	86% 156	74% 165	88% 206	82% 184
Ceftazidime	% Non-susceptible Reports with susceptiblility data	53% 176	69% 191	71% 171	70% 233	67% 258

A. calcoaceticus/baumannii

2003

2004

2005

2006

2007

Total reports:

359

374

400

413

399

Gentamicin

% Non-susceptible
Reports with susceptiblility data

22%

237

26%

285

23%

276

26%

313

21%

331

Amikacin

% Non-susceptible
Reports with susceptiblility data

11%

16%

21%

115

26%

187

22%

199

Tobramycin

% Non-susceptible
Reports with susceptiblility data

12%

14%

23%

25%

32%

114

Ciprofloxacin

% Non-susceptible
Reports with susceptiblility data

30%

231

36%

266

30%

269

36%

319

30%

326

Imipenem

% Non-susceptible
Reports with susceptiblility data

21%

126

24%

173

Meropenem

% Non-susceptible
Reports with susceptiblility data

13%

128

20%

126

35%

175

22%

175

Cefotaxime

% Non-susceptible
Reports with susceptiblility data

80%

121

86%

156

74%

165

88%

206

82%

184

Ceftazidime

% Non-susceptible
Reports with susceptiblility data

53%

176

69%

191

71%

171

70%

233

67%

258

* Data extracted 8 of January 2008

For A. calcoaceticus/baumannii, the only statistically significant changes in susceptibility (measured by chi-square test for trend and controlling for inter-laboratory variation), from 2003 to 2007, were observed for imipenem (7% to 24%; P=0.018), and meropenem (3% to 22%;P<0.0001). There were no statistically significant trends for gentamicin (21%), amikacin (22%), tobramycin (32%), ciprofloxacin (30%), cefotaxime (82%) or ceftazidime (67%).

Table 4 Antibiotic susceptibility data for reports of A. lwoffii bacteraemia, England, Wales, and Northern Ireland: 2003 to 2007*

*A. Iwoffii*	2003	2004	2005	2006	2007
Total reports:	186	224	223	246	293
Gentamicin	% Non-susceptible Reports with susceptiblility data	3% 137	1% 150	1% 154	5% 191	4% 235
Amikacin	% Non-susceptible Reports with susceptiblility data	3% 40	5% 44	0% 54	2% 87	2% 124
Tobramycin	% Non-susceptible Reports with susceptiblility data	8% 12	0% 27	0% 25	10% 29	7% 44
Ciprofloxacin	% Non-susceptible Reports with susceptiblility data	5% 119	5% 144	5% 151	6% 190	5% 225
Imipenem	% Non-susceptible Reports with susceptiblility data	2% 46	0% 34	0% 57	4% 72	0% 110
Meropenem	% Non-susceptible Reports with susceptiblility data	3% 33	0% 65	4% 67	4% 73	3% 120
Cefotaxime	% Non-susceptible Reports with susceptiblility data	27% 63	20% 74	32% 99	23% 120	23% 143
Ceftazidime	% Non-susceptible Reports with susceptiblility data	24% 75	23% 91	21% 121	13% 148	25% 187

A. Iwoffii

2003

2004

2005

2006

2007

Total reports:

186

224

223

246

293

Gentamicin

% Non-susceptible
Reports with susceptiblility data

137

150

154

191

235

Amikacin

% Non-susceptible
Reports with susceptiblility data

124

Tobramycin

% Non-susceptible
Reports with susceptiblility data

10%

Ciprofloxacin

% Non-susceptible
Reports with susceptiblility data

119

144

151

190

225

Imipenem

% Non-susceptible
Reports with susceptiblility data

110

Meropenem

% Non-susceptible
Reports with susceptiblility data

120

Cefotaxime

% Non-susceptible
Reports with susceptiblility data

27%

20%

32%

23%

120

23%

143

Ceftazidime

% Non-susceptible
Reports with susceptiblility data

24%

23%

21%

121

13%

148

25%

187

* Data extracted 8 of January 2008

For A. lwoffii, there were no statistically signficant changes in resistance rates between 2003 and 2007 for gentamicin (4% resistant in 2007), amikacin (2%), tobramycin (7%), ciprofloxacin (5%), imipenem (0%), meropenem (3%), cefotaxime (23%), or ceftazidime (25%).

Last reviewed: 9 March 2010